Aemetis, Inc. (NASDAQ:AMTX) Short Interest Down 17.9% in November

Aemetis, Inc. (NASDAQ:AMTX) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 5,540,000 shares, a decrease of 17.9% from the October 31st total of 6,750,000 shares. Based on an average trading volume of 670,300 shares, the days-to-cover ratio is currently 8.3 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AMTX. UBS Group decreased their target price on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a research report on Monday, August 19th. Ascendiant Capital Markets lowered their target price on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Aemetis in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.95.

Aemetis Trading Up 3.3 %

AMTX stock traded up $0.13 during mid-day trading on Friday, hitting $4.09. The stock had a trading volume of 372,450 shares, compared to its average volume of 803,372. Aemetis has a 1-year low of $2.10 and a 1-year high of $7.03. The company has a fifty day moving average of $3.12 and a 200 day moving average of $3.06. The stock has a market capitalization of $203.44 million, a price-to-earnings ratio of -1.81 and a beta of 1.23.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. The firm had revenue of $81.44 million during the quarter, compared to analyst estimates of $77.79 million. During the same quarter in the prior year, the company posted ($0.59) EPS. As a group, sell-side analysts expect that Aemetis will post -2.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aemetis

Several institutional investors and hedge funds have recently modified their holdings of AMTX. State Board of Administration of Florida Retirement System bought a new position in Aemetis during the first quarter valued at about $84,000. Bank of New York Mellon Corp acquired a new position in shares of Aemetis during the 2nd quarter valued at about $306,000. Rhumbline Advisers raised its stake in shares of Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after acquiring an additional 50,528 shares in the last quarter. Hutchinson Capital Management CA acquired a new stake in Aemetis in the 2nd quarter worth approximately $70,000. Finally, Susquehanna Fundamental Investments LLC boosted its position in Aemetis by 287.4% during the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after purchasing an additional 93,536 shares during the period. Institutional investors and hedge funds own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.